Kiniksa stock rocketed 20% after first-quarter results on April 29. The biotech stock then broke out of a cup base with a buy point of 28.15 on May 5. IBD MarketSurge shows that shares traded tightly ...

Regeneron’s shares (currently trading at $552.99) have posted a disappointing 18.9% loss, well below the S&P 500’s 4.5% gain.

Firstly, he noted that the launch of Eylea HD has exceeded expectations to date, contributing to a positive outlook for the company’s performance. Furthermore, the Dupixent COPD phase 3 readout ...

Regeneron Pharmaceuticals Inc. closed 55.21% below its 52-week high of $1,211.20, which the company reached on August 27th.

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst ...

Flynn’s outlook, therefore, reflects a belief in the strength of Regeneron’s product pipeline and market strategy.

On investments, Regeneron's focus has largely been on developing its internal pipeline of oncology and immunology therapies, but collaborations have increased in recent years.

Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Despite these challenges, Bernstein analysts anticipate that Regeneron's stock will likely be range-bound during the first half of 2025.

In a challenging market environment, Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock has reached its 52-week low, trading at $641.91.

On investments, Regeneron's focus has largely been on developing its internal pipeline of oncology and immunology therapies, but collaborations have increased in recent years.